Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
Portfolio Pulse from
Genmab announced that the net sales of DARZALEX, a product for which they receive royalties from Johnson & Johnson, reached USD 11,670 million in 2024. The sales were USD 6,588 million in the U.S. and USD 5,082 million internationally.
January 22, 2025 | 11:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab's announcement of DARZALEX sales reaching USD 11,670 million in 2024 is significant as the company receives royalties from these sales. This could positively impact Genmab's revenue and stock price.
Genmab receives royalties from DARZALEX sales, which totaled USD 11,670 million in 2024. This substantial sales figure suggests a positive impact on Genmab's revenue, likely boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Johnson & Johnson reported DARZALEX sales of USD 11,670 million in 2024, indicating strong performance of this product. This could positively influence J&J's financial results and stock price.
The reported sales of DARZALEX by J&J indicate strong market performance, which is likely to positively impact J&J's financial results and investor sentiment, potentially boosting the stock price.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70